Sustol Injection
Product Images NDC 47426-101

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Sustol (NDC 47426-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heron Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of The Chemical Structure (Sustol 01)

Chemical structure of granisetron, the active ingredient in SUSTOL injection. The diagram shows molecular bonds and arrangement relevant to granisetron's chemical makeup.*

FDA Label Image

Image Of Figure 1 (Sustol 02)

A line graph illustrating the concentration of SUSTOL (granisetron) in ng/mL over time in hours, showing data points with error bars and a sample size of 142 subjects. The concentration peaks early, gradually decreases over approximately 168 hours, reflecting the drug's pharmacokinetic profile after subcutaneous injection.*

FDA Label Image

Image Of Six Pack Carton (Principle Panel)

SUSTOL (granisetron) extended-release injection 10 mg/0.4 mL, subcutaneous injection. The label indicates the product contains six single-dose pre-filled syringe units. The packaging is primarily white and blue with red text stating 'For subcutaneous use only.' It is labeled as a prescription drug by Heron Therapeutics, Inc.*

FDA Label Image

Image Of Ifu Instruction 1 (Sustol 05)

An instructional illustration showing packaging steps for a product. It includes an arrow pointing from the open tray containing two sealed packets to a closed shipping box. A '60 MIN' label is displayed inside a circle, indicating a time-related instruction.*

FDA Label Image

Image Of Ifu Instruction 2 (Sustol 06)

An instructional illustration showing a subcutaneous injection syringe with a zoomed-in view highlighting the syringe plunger's seal or stopper area, indicated by a red arrow.*

FDA Label Image

Image Of Ifu Instruction 3 (Sustol 07)

An instructional illustration showing a person holding a syringe and a device, demonstrating how to twist or turn the syringe cap or component, indicated by a red curved arrow. This likely depicts part of the preparation or assembly process for a subcutaneous injection.*

FDA Label Image

Image Of Ifu Instruction 4 (Sustol 08)

An instructional illustration depicting a subcutaneous injection device for SUSTOL (granisetron) 10 mg/0.4 mL. The image shows a syringe with a plunger and two sealed packaging pouches, likely for the syringe and needle or related components. The depiction is clear and intended to demonstrate components of the injection product by Heron Therapeutics, Inc.*

FDA Label Image

Image Of Ifu Instruction 5 (Sustol 09)

An instructional illustration showing two hands opening a sealed foil pouch, demonstrating the initial step to access a contained product, likely related to a medication or medical device.*

FDA Label Image

Image Of Ifu Instruction 6 (Sustol 10)

An instructional illustration depicting the use of a syringe with a vial or pouch for injection preparation. It includes a callout indicating a 5 to 6 minute time interval, likely referring to an administration or preparation step.*

FDA Label Image

Image Of Ifu Instruction 7 (Sustol 11)

An illustration showing a thermometer indicating a temperature of 37°C and a circular icon with the text '<15 MIN', likely representing a temperature target and a time duration.*

FDA Label Image

Image Of Ifu Instruction 8 (Sustol 12)

An instructional anatomical illustration showing recommended and not recommended subcutaneous injection sites for SUSTOL (granisetron) injection. The image depicts the front and back of a human figure with highlighted areas on the upper arms for injection and a crossed-out symbol over the abdomen, indicating it is not a recommended injection site.*

FDA Label Image

Image Of Ifu Instruction 9 (Sustol 13)

An instructional illustration showing the proper subcutaneous injection technique for SUSTOL (granisetron) injection. It depicts a hand holding a syringe angled between 30 and 45 degrees relative to the skin surface during administration.*

FDA Label Image

Image Of Ifu Instruction 10 (Sustol 14)

An instructional illustration showing a hand holding a syringe and another hand holding a needle. The drawing demonstrates a step where the needle is being inserted into the syringe, with a note stating 'OPTIONAL ONCE NEEDLE INSERTED' above the hands.*

FDA Label Image

Image Of Ifu Instruction 11 (Sustol 15)

Illustration showing a subcutaneous injection technique with a syringe and needle. A close-up view highlights an arrow pointing to the needle hub, emphasizing correct attachment or positioning for administering the injection.*

FDA Label Image

Image Of Ifu Instruction 12 (Sustol 16)

An instructional diagram showing the use of a SUSTOL injection device with a subcutaneous needle. The image depicts the syringe above a vial or injection port with a red arrow indicating the downward movement to connect or withdraw medication. The right side shows the syringe fully engaged with the vial or port, illustrating the setup for subcutaneous injection.*

FDA Label Image

Image Of Ifu Instruction (Caution)

SUSTOL 10 mg/0.4 mL subcutaneous injection by Heron Therapeutics, Inc. The label includes a prominent orange caution warning.*

FDA Label Image

Image Of Ifu Instruction (Optional)

FDA Label Image

Image Of Ifu Instruction (Warning)

A warning text panel containing the word 'WARNING' in white letters on a red background. The image highlights a cautionary message, typically found on pharmaceutical product inserts or labels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.